Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsMarcus Maurer, Baldrich Esther Serra, Ana M. Giménez‐Arnau et al.|The Lancet|2023Cited by 69